
![]() |
| Click here to enlarge |
Deal particulars: Jubilant Organosys has entered into a $255-million (Rs 1,020 crore) agreement with Draxis Health, a Canadian radiopharmaceutical and contract manufacturing company, to take it over. The transaction is expected to close in the second quarter of 2008.
Impact analysis: Draxis Health has two business divisions: Draximage, its radiopharmaceutical division, and Draxis Pharma, its contract manufacturing business. One of the major attractions for Jubilant is Draxis’s multi-year $120 million (Rs 480 crore) contract for supplying multiple non-sterile specialty semi-solid products to J&J. Through this acquisition, Jubilant will become one of the leading contract manufacturers of small volume parenterals feeding large pharmaceuticals and biotech companies in North America.